Literature DB >> 17503783

Structure of human hyaluronidase-1, a hyaluronan hydrolyzing enzyme involved in tumor growth and angiogenesis.

Kinlin L Chao1, Lavanya Muthukumar, Osnat Herzberg.   

Abstract

Mammalian hyaluronidases hydrolyze hyaluronan, a polysaccharide of diverse physiological roles found in all tissues and body fluids. In addition to its function in normal cellular hyaluronan turnover, human hyaluronidase-1 is implicated in cancer proliferation, angiogenesis, and inflammatory diseases; its expression is up-regulated in advanced stages of bladder cancer, whereas the expression of the alternative splice-variants is down-regulated. The crystal structure reveals a molecule composed of two closely associated domains: a catalytic domain that adopts a distorted (beta/alpha)8 barrel resembling that of bee venom hyaluronidase, and a novel, EGF-like domain, characteristic of involvement in protein-protein interactions and regulatory processes. The structure shows that the fold of this unique EGF-like domain is intact in four alternative splice-variants, whereas the catalytic domain is likely to be unfolded. Thus, these variants may function by competing with the full-length enzyme for the putative protein partner and regulating enzymatic activity in healthy cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17503783     DOI: 10.1021/bi700382g

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  37 in total

Review 1.  Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer.

Authors:  Ki Young Choi; Gurusamy Saravanakumar; Jae Hyung Park; Kinam Park
Journal:  Colloids Surf B Biointerfaces       Date:  2011-10-20       Impact factor: 5.268

2.  Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting.

Authors:  Shuangshuang Song; Huan Qi; Jingwen Xu; Pan Guo; Fen Chen; Fei Li; Xinggang Yang; Naicheng Sheng; Yingliang Wu; Weisan Pan
Journal:  Pharm Res       Date:  2014-05-20       Impact factor: 4.200

Review 3.  Ocular delivery of proteins and peptides: Challenges and novel formulation approaches.

Authors:  Abhirup Mandal; Dhananjay Pal; Vibhuti Agrahari; Hoang My Trinh; Mary Joseph; Ashim K Mitra
Journal:  Adv Drug Deliv Rev       Date:  2018-01-13       Impact factor: 15.470

4.  Hyaluronic Acid: Incorporating the Bio into the Material.

Authors:  Kayla J Wolf; Sanjay Kumar
Journal:  ACS Biomater Sci Eng       Date:  2019-01-27

5.  Unbinding of hyaluronan accelerates the enzymatic activity of bee hyaluronidase.

Authors:  Attila Iliás; Károly Liliom; Brigitte Greiderer-Kleinlercher; Stephan Reitinger; Günter Lepperdinger
Journal:  J Biol Chem       Date:  2011-08-12       Impact factor: 5.157

6.  Effect of anticoagulants on the plasma hyaluronidase activities.

Authors:  R Sharma; Y H Mahadeswaraswamy; K Harish Kumar; S Devaraja; K Kemparaju; B S Vishwanath; K S Girish
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 7.  Emerging roles for hyaluronidase in cancer metastasis and therapy.

Authors:  Caitlin O McAtee; Joseph J Barycki; Melanie A Simpson
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

8.  Hyaluronidase activity of human Hyal1 requires active site acidic and tyrosine residues.

Authors:  Ling Zhang; Alamelu G Bharadwaj; Andrew Casper; Joel Barkley; Joseph J Barycki; Melanie A Simpson
Journal:  J Biol Chem       Date:  2009-02-06       Impact factor: 5.157

9.  Designed human serum hyaluronidase 1 variant, HYAL1DeltaL, exhibits activity up to pH 5.9.

Authors:  Stephan Reitinger; Johannes Müllegger; Brigitte Greiderer; Jens Erik Nielsen; Günter Lepperdinger
Journal:  J Biol Chem       Date:  2009-05-28       Impact factor: 5.157

10.  KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding protein involved in hyaluronan depolymerization.

Authors:  Hiroyuki Yoshida; Aya Nagaoka; Ayumi Kusaka-Kikushima; Megumi Tobiishi; Keigo Kawabata; Tetsuya Sayo; Shingo Sakai; Yoshinori Sugiyama; Hiroyuki Enomoto; Yasunori Okada; Shintaro Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.